| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | Biomarker | group | BEFREE | Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC-IBD), share three major pathogenetic mechanisms of inflammatory bowel disease (IBD)-gut dysbiosis, gut barrier failure and immune system dysregulation. | 31337064 | 2019 | ||||
|
0.070 | Biomarker | group | BEFREE | The statin-exposed group had a longer IBD duration, longer follow-up period, and more colonoscopies but lower inflammatory scores, less frequent PSC and less use of thiopurines and biologics. | 30400722 | 2019 | ||||
|
0.070 | Biomarker | group | BEFREE | Our aim was to determine the clinical characteristics and management of PSC in IBD patients, and the factors associated with malignancies. | 31063540 | 2019 | ||||
|
0.070 | Biomarker | group | BEFREE | PSC is an autoimmune biliary inflammatory disorder that is often associated with inflammatory bowel disease (IBD), with 50%-75% of patients with PSC having coexisting IBD, most commonly ulcerative colitis. | 29411404 | 2018 | ||||
|
0.070 | Biomarker | group | BEFREE | Although no major differences were observed in the individual bile acid species in stool, their overall combination allowed a good separation between PSC-IBD and inflammatory bowel disease. | 29435321 | 2018 | ||||
|
0.070 | Biomarker | group | BEFREE | Patients with PSC-IBD treated with UDCA did not have less CDI than IBD patients. | 30524414 | 2018 | ||||
|
0.070 | Biomarker | group | BEFREE | PSC has a chronic, progressive course in children, and nearly half of patients develop an adverse liver outcome after 10 years of disease; elevations in bilirubin, gamma-glutamyltransferase, and aspartate aminotransferase-to-platelet ratio index at diagnosis can identify patients at highest risk; small duct PSC and PSC-inflammatory bowel disease are more favorable disease phenotypes.(Hepatology 2017;66:518-527). | 28390159 | 2017 |